Zepbound

From WikiMD's Food, Medicine & Wellness Encyclopedia

FDA Approves New Weight Management Drug Zepbound[edit | edit source]

Central Obesity
Obesity waist circumference

The U.S. Food and Drug Administration (FDA) has announced the approval of Zepbound (tirzepatide) for chronic weight management in adults, signifying a pivotal step in the treatment of obesity and overweight. Specifically targeting individuals with a body mass index (BMI) of 30 kg/m2 or greater, or those with a BMI of 27 kg/m2 or greater who also suffer from related conditions such as high blood pressure, type 2 diabetes, or high cholesterol, Zepbound is to be used alongside a reduced-calorie diet and increased physical activity for optimal efficacy.

Background on Tirzepatide[edit | edit source]

Previously approved under the trade name Mounjaro for the improvement of blood sugar levels in conjunction with dietary and exercise regimes in adults with type 2 diabetes, tirzepatide is now set to combat weight-related health issues as the active ingredient in Zepbound.

Statement from the FDA[edit | edit source]

John Sharretts, M.D., leading the Division of Diabetes, Lipid Disorders, and Obesity within the FDA’s Center for Drug Evaluation and Research, highlights the criticality of Zepbound's approval amidst the escalating prevalence of obesity and overweight in the United States. Such conditions are linked with some of the most common causes of death, including heart disease, stroke, and diabetes.

Injection

Obesity and Overweight in the U.S.[edit | edit source]

Statistics suggest that around 70% of American adults fall into the category of obesity or overweight, with a considerable number facing weight-related health challenges. Studies advocate that reducing body weight by 5% to 10% through dietary and physical activity modifications can notably diminish the risk of cardiovascular diseases in this population.

Mechanism of Action[edit | edit source]

The drug operates by engaging receptors for intestine-secreted hormones such as Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). By doing so, it effectively diminishes appetite and subsequently food intake. Administered via subcutaneous injection on a weekly basis, the dosage of Zepbound is escalated progressively, reaching target doses of 5 mg, 10 mg, or 15 mg.

Clinical Trials and Effectiveness[edit | edit source]

The efficacy of Zepbound in the realm of chronic weight management has been substantiated through two rigorous randomized, double-blind, placebo-controlled trials, involving a total of 3,477 patients. Post 72 weeks of treatment, those administered Zepbound exhibited substantial weight loss as opposed to their placebo-receiving counterparts, with a larger proportion achieving a minimum of 5% weight loss.

Results from Clinical Trials[edit | edit source]

In the most extensive non-diabetic adult trial, with an average initial weight of 231 pounds and BMI of 38 kg/m2, the highest dose of Zepbound yielded an average weight reduction of 18%. In contrast, a trial focusing on adults with type 2 diabetes commenced with average weights of 222 pounds and a BMI of 36 kg/m2; here, the highest dose of Zepbound led to an average weight loss of 12%.

Side Effects and Warnings[edit | edit source]

Zepbound administration can lead to adverse effects such as nausea, diarrhea, vomiting, constipation, abdominal discomforts, and hypersensitive reactions. Furthermore, the occurrence of thyroid C-cell tumors in rat studies raises concerns, although the transference of this risk to humans remains unconfirmed. Its use is thus contraindicated in individuals with a history of specific thyroid cancers or Multiple Endocrine Neoplasia syndrome type 2.

Patients with a history of severe gastrointestinal conditions or pancreatitis, as well as those currently on GLP-1 receptor agonists, should refrain from Zepbound use. The drug's labeling also cautions against potential pancreatitis, gallbladder issues, hypoglycemia, kidney damage, diabetic retinopathy, and thoughts or behaviors of suicide.

Approvals and Designations[edit | edit source]

The FDA's Priority Review and Fast Track designations for Zepbound underscore its significant therapeutic potential and the urgency of its availability to the public.

The approval honor falls to pharmaceutical innovator Eli Lilly and Co., marking another milestone in their distinguished history.

Availability[edit | edit source]

The manufacturer of Zepbound, Eli Lilly, announced on Dec 8th, 2023 that it is currently available at pharmacies in the United States. This introduction marks a significant step in the availability of innovative obesity treatments.

Cost[edit | edit source]

For customers who do not have health insurance coverage for Zepbound, Eli Lilly has set the price at an approachable rate of approximately $550 per month. This pricing strategy positions Zepbound competitively, as it is roughly half of its original list price of $1060, making it more affordable for a broader range of consumers.

Weight loss injection market[edit | edit source]

Zepbound enters a rapidly expanding market dedicated to weight-loss medications. Industry analysts project that by the end of this decade, the market for such drugs is expected to burgeon, reaching a staggering value of around $100 billion. This growth reflects an increasing demand for effective obesity treatments, spurred by a rising global prevalence of obesity and a growing awareness of its health implications. Zepbound's launch into this lucrative market signifies Eli Lilly's commitment to addressing the complex challenge of obesity with advanced pharmacological solutions.

Coupons and cost savings[edit | edit source]

The manufacturer offers cost saving cards for as low as $25.00 a month with commercial insurance. Access coupons and saving cards here

Cost:Commercial Insurance with Coverage for Zepbound[edit | edit source]

If you have commercial insurance with coverage for Zepbound, you may be eligible to pay as low as $25 for a 1-month or 3-month prescription with the Zepbound Savings Card for eligible, commercially insured patients with Zepbound coverage. Governmental beneficiaries excluded. Terms and conditions apply.

Commercial insurance without coverage[edit | edit source]

If you have commercial drug insurance but it does not cover Zepbound, you may pay as low as $550 for a 1-month supply of Zepbound for a 1-month supply of Zepbound.

Zepbound clinic locator[edit | edit source]

WikiMD's weight loss clinic locator (USA)

Obesity is a complex health condition characterized by an excessive amount of body fat. Finding the right weight loss doctor is crucial for a successful obesity management plan. Need help finding a weight loss clinic in the United States that might be willing to prescribe Zepbound, Wegovy, Ozempic, Mounjaro, Saxenda or other weight loss medications such as Phentermine?

Weight loss in AlabamaWeight loss in AlaskaWeight loss in ArizonaWeight loss in ArkansasWeight loss in CaliforniaWeight loss in ColoradoWeight loss in ConnecticutWeight loss in DelawareWeight loss in FloridaWeight loss in GeorgiaWeight loss in HawaiiWeight loss in IdahoWeight loss in IllinoisWeight loss in IndianaWeight loss in IowaWeight loss in KansasWeight loss in KentuckyWeight loss in LouisianaWeight loss in MaineWeight loss in MarylandWeight loss in MassachusettsWeight loss in MichiganWeight loss in MinnesotaWeight loss in MississippiWeight loss in MissouriWeight loss in MontanaWeight loss in NebraskaWeight loss in NevadaWeight loss in New HampshireWeight loss in New JerseyWeight loss in New MexicoWeight loss in New YorkWeight loss in North CarolinaWeight loss in North DakotaWeight loss in OhioWeight loss in OklahomaWeight loss in OregonWeight loss in PennsylvaniaWeight loss in Rhode IslandWeight loss in South CarolinaWeight loss in South DakotaWeight loss in TennesseeWeight loss in TexasWeight loss in UtahWeight loss in VermontWeight loss in VirginiaWeight loss in WashingtonWeight loss in West VirginiaWeight loss in WisconsinWeight loss in WyomingWeight loss in DelawareWeight loss in MarylandWeight loss in New HampshireWeight loss in New JerseyWeight loss in MassachusettsWeight loss in ConnecticutWeight loss in Washington DCWeight loss in West VirginiaWeight loss in VermontWeight loss in Rhode IslandMap of USA with state names 2.svg
About this image

Weight loss centers by state[edit source]

Official website[edit | edit source]

External links[edit | edit source]

Also see[edit | edit source]

W8MD weight loss locations[edit | edit source]

  • W8MD weight loss centers is one of the first weight loss centers in the United States to announce offering Zepbound injections for weight loss and can provide prescriptions to eligible patients.

Transform Your Life with W8MD Weight Loss Centers[edit source]

W8mdlogo.png
W8MD weight loss doctors team

W8MD offers a physician-supervised weight loss program at various locations including New York, Pennsylvania and New Jersey. Our centers provide expert medical guidance, accept most insurances, and offer telemedicine options for convenience.

Why choose W8MD?[edit source]

Book Your Appointment[edit source]

Start your weight loss journey today at our centers in New York, New Jersey and Pennsylvania and visit W8MD.com Call (718)946-5500

Zepbound Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD